{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T19:34:44Z","timestamp":1785180884202,"version":"3.55.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"Supplement_4","license":[{"start":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T00:00:00Z","timestamp":1697328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,16]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In this overview, we describe important contributions from the Antibacterial Resistance Leadership Group (ARLG) to patient care, clinical trials design, and mentorship while outlining future priorities. The ARLG research agenda is focused on 3 key areas: gram-positive infections, gram-negative infections, and diagnostics. The ARLG has developed an innovative approach to clinical trials design, the desirability of outcome ranking (DOOR), which uses an ordinal measure of global outcome to assess both benefits and harms. DOOR was initially applied to observational studies to determine optimal dosing of vancomycin for methicillin-resistant Staphylcococcus aureus bacteremia and the efficacy of ceftazidime-avibactam versus colistin for the treatment of carbapenem-resistant Enterobacterales infection. DOOR is being successfully applied to the analysis of interventional trials and, in collaboration with the US Food and Drug Administration (FDA), for use in registrational trials. In the area of diagnostics, the ARLG developed Master Protocol for Evaluating Multiple Infection Diagnostics (MASTERMIND), an innovative design that allows simultaneous testing of multiple diagnostic platforms in a single study. This approach will be used to compare molecular assays for the identification of fluoroquinolone-resistant Neisseria gonorrhoeae (MASTER GC) and to compare rapid diagnostic tests for bloodstream infections. The ARLG has initiated a first-in-kind randomized, double-blind, placebo-controlled trial in participants with cystic fibrosis who are chronically colonized with Pseudomonas aeruginosa to assess the pharmacokinetics and antimicrobial activity of bacteriophage therapy. Finally, an engaged and highly trained workforce is critical for continued and future success against antimicrobial drug resistance. Thus, the ARLG has developed a robust mentoring program targeted to each stage of research training to attract and retain investigators in the field of antimicrobial resistance research.<\/jats:p>","DOI":"10.1093\/cid\/ciad475","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T14:30:37Z","timestamp":1697466637000},"page":"S279-S287","source":"Crossref","is-referenced-by-count":10,"title":["The Antibacterial Resistance Leadership Group: Scientific Advancements and Future Directions"],"prefix":"10.1093","volume":"77","author":[{"given":"Henry F","family":"Chambers","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, University of California \u2013San Francisco, San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather R","family":"Cross","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Souli","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott R","family":"Evans","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, George Washington University , Washington, DC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Mayo Clinic , Rochester, Minnesota , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8048-0897","authenticated-orcid":false,"suffix":"Jr.","given":"Vance G","family":"Fowler","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine , Durham, North Carolina , USA"},{"name":"Division of Infectious Diseases, Department of Medicine, Duke University School of Medicine , Durham, North Carolina , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Antibacterial Resistance Leadership Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Lodise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancie","family":"Deckard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivra","family":"Bunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Holland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smitha","family":"Zaharoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrabani","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Wickward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Waller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"van Duin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keri","family":"Baum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Komarow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minggui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhao","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhigya","family":"Giri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixiao","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Diao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Fidler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanying","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nyssa","family":"Schwager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Bonomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Mau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Satlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranita","family":"Tamma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Schooley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimitsu","family":"Hamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Sund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant","family":"Booth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Estes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerryl","family":"Greenwood-Quaintance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krupa Mukesh","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Doernberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Dodd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ephraim","family":"Tsalik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayani","family":"Tillekeratne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praneeta","family":"Raza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritu","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Abbenante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Mocka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tori","family":"Kinamon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Howard-Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Geres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijie","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Mehigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Varduhi","family":"Ghazaryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seema","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Raterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamika","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,10,16]]},"reference":[{"key":"2023101612060865500_ciad475-B1","doi-asserted-by":"crossref","first-page":"e01809-20","DOI":"10.1128\/AAC.01809-20","article-title":"Pharmacokinetic and pharmacodynamic profiling of minocycline for injection following a single infusion in critically ill adults in a phase IV open-label multicenter study (ACUMIN)","volume":"65","author":"Lodise","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2023101612060865500_ciad475-B2","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1093\/jac\/dkaa197","article-title":"Determining the optimal dosing of a novel combination regimen of ceftazidime\/avibactam with aztreonam against NDM-1-producing Enterobacteriaceae using a hollow-fibre infection model","volume":"75","author":"Lodise","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2023101612060865500_ciad475-B3","doi-asserted-by":"crossref","first-page":"e0093522","DOI":"10.1128\/aac.00935-22","article-title":"Safety of ceftazidime-avibactam in combination with aztreonam (COMBINE) in a phase I, open-label study in healthy adult volunteers","volume":"66","author":"Lodise","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2023101612060865500_ciad475-B4","doi-asserted-by":"crossref","first-page":"e0093622","DOI":"10.1128\/aac.00936-22","article-title":"Pharmacokinetics of ceftazidime-avibactam in combination with aztreonam (COMBINE) in a phase 1, open-label study of healthy adults","volume":"66","author":"Lodise","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2023101612060865500_ciad475-B5","doi-asserted-by":"crossref","first-page":"e00464","DOI":"10.1128\/AAC.00464-18","article-title":"Phase I study to evaluate the pharmacokinetics, safety, and tolerability of two dosing regimens of oral fosfomycin tromethamine in healthy adult participants","volume":"62","author":"Wenzler","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2023101612060865500_ciad475-B6","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/cid\/ciz460","article-title":"The emperor\u2019s new clothes: prospective observational evaluation of the association between initial vancomycIn exposure and failure rates among adult hospitalized patients with methicillin-resistant Staphylococcus aureus bloodstream infections (PROVIDE)","volume":"70","author":"Lodise","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023101612060865500_ciad475-B7","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1186\/s13063-022-06370-1","article-title":"Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial","volume":"23","author":"Turner","year":"2022","journal-title":"Trials"},{"key":"2023101612060865500_ciad475-B8","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae","volume":"66","author":"van Duin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2023101612060865500_ciad475-B9","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1186\/s13063-022-07047-5","article-title":"Safety and microbiological activity of phage therapy in persons with cystic fibrosis colonized with Pseudomonas aeruginosa: study protocol for a phase 1b\/2, multicenter, randomized, double-blind, placebo-controlled trial","volume":"23","author":"Tamma","year":"2022","journal-title":"Trials"},{"key":"2023101612060865500_ciad475-B10","first-page":"50","article-title":"Isolation and characterization of lytic bacteriophages targeting diverse Enterobacter spp. clinical isolates","volume":"3","author":"Finney","year":"2022","journal-title":"Phage (New Rochelle)"},{"key":"2023101612060865500_ciad475-B11","doi-asserted-by":"crossref","first-page":"104372","DOI":"10.1016\/j.isci.2022.104372","article-title":"Genomic characterization of lytic bacteriophages targeting genetically diverse Pseudomonas aeruginosa clinical isolates","volume":"25","author":"Nordstrom","year":"2022","journal-title":"iScience"},{"key":"2023101612060865500_ciad475-B12","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1001\/jamapediatrics.2021.5547","article-title":"Short- vs standard-course outpatient antibiotic therapy for community-acquired pneumonia in children: the SCOUT-CAP randomized clinical trial","volume":"176","author":"Williams","year":"2022","journal-title":"JAMA Pediatr"},{"key":"2023101612060865500_ciad475-B13","doi-asserted-by":"crossref","first-page":"e0019522","DOI":"10.1128\/mbio.00195-22","article-title":"Comparison of the respiratory resistomes and microbiota in children receiving short versus standard course treatment for community-acquired pneumonia","volume":"13","author":"Pettigrew","year":"2022","journal-title":"mBio"},{"key":"2023101612060865500_ciad475-B14","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/S1473-3099(22)00735-6","article-title":"Efficacy and safety of azithromycin versus placebo to treat lower respiratory tract infections associated with low procalcitonin: a randomised, placebo-controlled, double-blind, non-inferiority trial","volume":"23","author":"Tsalik","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2023101612060865500_ciad475-B15","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1128\/AAC.02636-14","article-title":"Surveillance of carbapenem-resistant Klebsiella pneumoniae: tracking molecular epidemiology and outcomes through a regional network","volume":"58","author":"van Duin","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2023101612060865500_ciad475-B16","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S1473-3099(19)30755-8","article-title":"Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study [published correction appears in Lancet Infect Dis. 2020 Apr 23]","volume":"20","author":"van Duin","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"2023101612060865500_ciad475-B17","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S1473-3099(21)00399-6","article-title":"Clinical outcomes and bacterial characteristics of carbapenem-resistant Klebsiella pneumoniae complex among patients from different global regions (CRACKLE-2): a prospective, multicentre, cohort study","volume":"22","author":"Wang","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2023101612060865500_ciad475-B18","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/S2666-5247(22)00329-9","article-title":"Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study","volume":"4","author":"Reyes","year":"2023","journal-title":"Lancet Microbe"},{"key":"2023101612060865500_ciad475-B19","doi-asserted-by":"crossref","first-page":"ofac572","DOI":"10.1093\/ofid\/ofac572","article-title":"Clinical impact of ceftriaxone resistance in Escherichia coli bloodstream infections: a multicenter prospective cohort study","volume":"9","author":"Tamma","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2023101612060865500_ciad475-B20","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1093\/cid\/ciz437","article-title":"Average weighted accuracy: pragmatic analysis for a rapid diagnostics in categorizing acute lung infections (RADICAL) study","volume":"70","author":"Liu","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023101612060865500_ciad475-B21","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1097\/CCM.0000000000005085","article-title":"Discriminating bacterial and viral infection using a rapid host gene expression test","volume":"49","author":"Tsalik","year":"2021","journal-title":"Crit Care Med"},{"key":"2023101612060865500_ciad475-B22","doi-asserted-by":"crossref","first-page":"322ra11","DOI":"10.1126\/scitranslmed.aad6873","article-title":"Host gene expression classifiers diagnose acute respiratory illness etiology","volume":"8","author":"Tsalik","year":"2016","journal-title":"Sci Transl Med"},{"key":"2023101612060865500_ciad475-B23","first-page":"2314","article-title":"Simultaneous evaluation of diagnostic assays for pharyngeal and rectal Neisseria gonorrhoeae and Chlamydia trachomatis using a master protocol","volume":"71","author":"Doernberg","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2023101612060865500_ciad475-B24","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1093\/cid\/civ447","article-title":"Randomized trial of rapid multiplex polymerase chain reaction-based blood culture identification and susceptibility testing","volume":"61","author":"Banerjee","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2023101612060865500_ciad475-B25","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1093\/cid\/ciaa528","article-title":"Randomized trial evaluating clinical impact of RAPid IDentification and susceptibility testing for gram-negative bacteremia: RAPIDS-GN","volume":"73","author":"Banerjee","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023101612060865500_ciad475-B26"},{"key":"2023101612060865500_ciad475-B27","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1093\/cid\/ciac952","article-title":"Reporting of antimicrobial resistance from blood cultures, an Antibacterial Resistance Leadership Group survey summary: resistance marker reporting practices from positive blood cultures","volume":"76","author":"Simner","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2023101612060865500_ciad475-B28","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciad538","article-title":"The future ain\u2019t what it used to be\u2026out with the old\u2026in with the better: Antibacterial Resistance Leadership Group (ARLG) innovations","volume":"77","author":"Evans","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2023101612060865500_ciad475-B29","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1093\/cid\/ciac829","article-title":"Doernberg SB; Antibacterial Resistance Leadership Group. Clinically adjudicated reference standards for evaluation of infectious diseases diagnostics","volume":"76","author":"Patel","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2023101612060865500_ciad475-B30","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa1914433","article-title":"Multidrug-resistant bacterial infections in U.S. hospitalized patients, 2012\u20132017","volume":"382","author":"Jernigan","year":"2020","journal-title":"N Engl J Med"},{"key":"2023101612060865500_ciad475-B31","first-page":"629","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis [published correction appears in Lancet. 2022 Oct 1; 400(10358):1102]","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","journal-title":"Lancet"},{"key":"2023101612060865500_ciad475-B32","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"2023101612060865500_ciad475-B33","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1093\/cid\/ciab295","article-title":"Infectious Diseases Society of America guidance on the treatment of extended-spectrum \u03b2-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa)","volume":"72","author":"Tamma","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2023101612060865500_ciad475-B34","doi-asserted-by":"crossref","first-page":"e02243-16","DOI":"10.1128\/AAC.02243-16","article-title":"Can ceftazidime-avibactam and aztreonam overcome \u03b2-lactam resistance conferred by metallo-\u03b2-lactamases in Enterobacteriaceae?","volume":"61","author":"Marshall","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2023101612060865500_ciad475-B35","doi-asserted-by":"crossref","first-page":"e0207121","DOI":"10.1128\/aac.02071-21","article-title":"Considerations for the use of phage therapy in clinical practice","volume":"66","author":"Suh","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2023101612060865500_ciad475-B36","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/cid\/ciw788","article-title":"MASTERMIND: bringing microbial diagnostics to the clinic","volume":"64","author":"Patel","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2023101612060865500_ciad475-B37","doi-asserted-by":"crossref","first-page":"e1157","DOI":"10.1093\/cid\/ciac692","article-title":"Improving traditional registrational trial end points: development and application of a desirability of outcome ranking end point for complicated urinary tract infection clinical trials","volume":"76","author":"Howard-Anderson","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2023101612060865500_ciad475-B38","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/cid\/ciad239","article-title":"Exploration of a potential DOOR endpoint for complicated intra-abdominal infections using nine registrational trials for antibacterial drugs","volume":"22","author":"Kinamon","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2023101612060865500_ciad475-B39"},{"key":"2023101612060865500_ciad475-B40","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/cid\/ciw329","article-title":"Benefit-risk evaluation for diagnostics: a framework (BED-FRAME)","volume":"63","author":"Evans","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2023101612060865500_ciad475-B41","author":"Antibacterial Resistance Leadership Group"},{"key":"2023101612060865500_ciad475-B42","author":"Federal Task Force on Combating Antibiotic-Resistant Bacteria"},{"key":"2023101612060865500_ciad475-B43","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.cmi.2023.04.004","article-title":"Which trial do we need? Next-generation sequencing to individualize therapy in Staphylococcus aureus bacteraemia","volume":"29","author":"Mourad","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"2023101612060865500_ciad475-B44","doi-asserted-by":"publisher","first-page":"e00464-18","DOI":"10.1128\/AAC.00464-18","article-title":"Phase I study to evaluate the pharmacokinetics, safety, and tolerability of two dosing regimens of oral fosfomycin tromethamine in healthy adult participants","volume":"62","author":"Wenzler","year":"2018","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/77\/Supplement_4\/S279\/52173587\/ciad475.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/77\/Supplement_4\/S279\/52173587\/ciad475.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T22:59:42Z","timestamp":1702940382000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/77\/Supplement_4\/S279\/7318053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,15]]},"references-count":44,"journal-issue":{"issue":"Supplement_4","published-online":{"date-parts":[[2023,10,16]]},"published-print":{"date-parts":[[2023,10,16]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciad475","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10,15]]},"published":{"date-parts":[[2023,10,15]]}}}